NCT05862285 2026-04-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
Clinical Trials
5 trialsNCT06754501 2026-02-18
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05394337 2025-10-09
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03708224 2025-01-28
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
University of California, San Francisco
Phase 2 Recruiting
NCT05259319 2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1 Unknown